Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Tikagrelor untuk sindrom koroner akut

Penilaian teknologi kesehatan PTK-B01AC24 Draf untuk telaah Diperbarui 14 Juni 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Tikagrelor ditambah aspirinRp 133,3 juta7,11213,35
klopidogrel ditambah aspirinRp 125,0 juta6,91612,92
SelisihRp 8,3 juta0,197-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
-1001020-0,200,000,200,400,60Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta96,8%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-10-50510transition rates annual post ACS event free to dead yr1 comparatortransition rates annual post ACS e...transition rates annual post ACS event free to dead yr1 interventiontransition rates annual post ACS e...transition rates annual post major bleed to deadtransition rates annual post major...utility values post major bleedutility values post major bleedinterventions ticagrelor aspirin drug cost idr per courseinterventions ticagrelor aspirin d...annual care costs idr post recurrent miannual care costs idr post recurre...annual care costs idr post major bleedannual care costs idr post major b...transition rates annual post recurrent mi to deadtransition rates annual post recur...annual care costs idr post strokeannual care costs idr post strokeutility values post recurrent miutility values post recurrent miPerubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (30 yr)0,197Rp 8,3 jutaRp 42,3 juta
5-year horizon0,045Rp 6,8 jutaRp 153,0 juta
10-year horizon0,103Rp 7,3 jutaRp 70,6 juta
20-year horizon0,168Rp 8,0 jutaRp 47,6 juta
0% discount rate0,285Rp 9,4 jutaRp 33,1 juta
5% discount rate0,158Rp 7,8 jutaRp 49,3 juta
Originator Brilinta retail pricing (ticagrelor at ~Rp 16.6 million/yr, no e-Katalog discount)0,197Rp 18,4 jutaRp 93,8 juta
Higher real-world Indonesian ACS event risk (year-1 MI and death x1.3; reflects late presentation / limited reperfusion access)0,229Rp 8,4 jutaRp 36,6 juta

5. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).

Luaran pembandingPrediksi modelData terbitSumber
Recurrent myocardial infarction, year 1 (clopidogrel + aspirin arm)5,8%5,8%PLATO clopidogrel-arm 12-month myocardial infarction ~5.8% (Wallentin NEJM 2009).
Stroke, year 1 (clopidogrel + aspirin arm)1,3%1,3%PLATO clopidogrel-arm 12-month stroke ~1.3% (Wallentin NEJM 2009).
PLATO-defined major bleeding, year 1 (clopidogrel + aspirin arm)11,6%11,6%PLATO clopidogrel-arm PLATO-defined major bleeding 11.6% at 12 months (Wallentin NEJM 2009; major-bleeding HR ticagrelor
All-cause mortality, year 1 (clopidogrel + aspirin arm)5,9%5,9%PLATO clopidogrel-arm all-cause death 5.9% at 12 months (Wallentin NEJM 2009; ticagrelor 4.5%, HR 0.78).
Cumulative all-cause mortality at 10 years post-ACS (clopidogrel + aspirin arm)51,9%40,0%Long-term post-ACS / post-MI registries report a wide ~30-50% 10-year all-cause mortality range for cohorts aged ~62 at

6. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • Threshold: WHO-CHOICE proxy 1x PDB Rp 75 million/QALY; 3x PDB Rp 225 million/QALY (not an official InaHTAC threshold).
  • Comparator choice is clinical- and policy-driven: clopidogrel + aspirin is the Fornas-listed, JKN-reimbursed default oral DAPT for ACS in Indonesia, so the policy-relevant question is the incremental value of switching to ticagrelor, mirroring NICE TA236.
  • Drug prices ADJUDICATED to Indonesian e-Katalog LKPP (BPJS procurement): generic ticagrelor 90 mg Rp 8,325/tablet (Hexpharm Jaya, Dexa Medica) and generic clopidogrel 75 mg Rp 715/tablet (six suppliers). The 12-month DAPT drug-cost differential is therefore ~Rp 5.8 million, far smaller than the originator-Brilinta gap and materially improving ticagrelor's relative value at scale.
  • Ticagrelor (Brilinta 90 mg, BPOM reg. DKI1635301117A1) is BPOM-registered and commercially available in Indonesia, with multiple generic products now on e-Katalog; the live policy question is reimbursement parity with clopidogrel under JKN/Fornas.
  • PNPK 2019 Tata Laksana Sindroma Koroner Akut (Kepmenkes HK.01.07/MENKES/675/2019) and PERKI guidelines position potent P2Y12 inhibitors (ticagrelor/prasugrel) as preferred over clopidogrel for many ACS patients, so reimbursed access lags guideline preference.
  • Budget impact is driven by the large incident ACS cohort initiating DAPT each year and by ticagrelor's negotiated e-Katalog price; reviewers should verify the current Fornas listing/restriction wording for ticagrelor and the latest e-Katalog tender prices before interpreting acquisition-cost scenarios.